These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 1387972)

  • 1. Studies of immune response to hepatitis B vaccine in Thai blood donors.
    Nuchprayoon C; O-Charoen RO; Vaivanijkul J; Apirakyothin T; Akkawat R; Chumnijarakij T
    Southeast Asian J Trop Med Public Health; 1992 Mar; 23(1):17-21. PubMed ID: 1387972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the immune response of four different dosages of a yeast-recombinant hepatitis B vaccine in Singapore children: a four-year follow-up study.
    Goh KT; Tan KL; Kong KH; Oon CJ; Chan SH
    Bull World Health Organ; 1992; 70(2):233-9. PubMed ID: 1600584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of recombinant yeast-derived hepatitis B vaccine in haemodialysis patients.
    Fujiyama S; Yoshida K; Sato T; Shimada H; Deguchi T
    Hepatogastroenterology; 1990 Dec; 37 Suppl 2():140-4. PubMed ID: 2150664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B vaccine: immune response in student nurses. A fifteen-month follow-up.
    Farisano G; Benussi G; Bonello C; Chiaramonte M; Gasparini V; Naccarato R; Renzulli G; Trivello R
    Boll Ist Sieroter Milan; 1986; 65(6):473-6. PubMed ID: 2953357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial of hepatitis B vaccine in a simplified immunization programme.
    Coursaget P; Yvonnet B; Sarr M; Vincelot P; Tortey E; Mboup S; Chiron JP; Diop-Mar I
    Bull World Health Organ; 1986; 64(6):867-71. PubMed ID: 2951032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intramuscular versus low-dose intradermal hepatitis B vaccine. Assessment by humoral and cellular immune response to hepatitis B surface antigen.
    Frazer IH; Jones B; Dimitrakakis M; Mackay IR
    Med J Aust; 1987 Mar; 146(5):242-5. PubMed ID: 2950303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunogenicity of vaccines against viral hepatitis A and B in the population above 40 years of age -- impact of risk factors].
    Chlíbek R; Smetana J; Sindelár R; Cecetková B; Prymula R; Kohl I
    Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):119-28. PubMed ID: 17900060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Safety and immunogenicity of Bilive combined hepatitis A and B vaccine].
    Zhao YL; Chen YG; Li J; Han GX; Tian C; Liang JL; Li G; Wang ZG; Zhu YG; Tian ZN; Zhang HY; Wan ZJ; Liang ZL; Bi SL
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Jun; 25(6):470-3. PubMed ID: 15231119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Persistence of HB vaccine immune protection and response to hepatitis B booster immunization].
    Li H; Li R; Liao S; Yang J; Zeng X
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Feb; 20(1):54-9. PubMed ID: 11367735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of a DNA-recombinant hepatitis B vaccine (Engerix B) given at 3, 5 and 11 months of age with a new schedule suitable for mass vaccination programmes.
    Piazza M; Da Villa G; Picciotto L; Abrescia N; Guadagnino V; Vegnente A; Iorio R; Cimmino L; Memoli AM
    Boll Soc Ital Biol Sper; 1989 Oct; 65(10):1003-8. PubMed ID: 2533872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8-10-year-old children.
    Duval B; Gîlca V; Boulianne N; Deceuninck G; Rochette L; De Serres G
    Vaccine; 2005 Jul; 23(31):4082-7. PubMed ID: 15963363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune response to hepatitis B vaccine in infants and newborns: control trial in an endemic area (Senegal).
    Coursaget P; Deciron F; Tortey E; Barin F; Chiron JP; Yvonnet B; Diouf C; Denis F; Diop-Mar I; Correa P
    IARC Sci Publ; 1984; (63):319-35. PubMed ID: 6242150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Seroconversion following immunization with a plasma-derived vaccine against hepatitis B: study of a 3-injection protocol (0, 1, 6 months) in Brazzaville (Congo)].
    Taty-Taty R; Saliou P; Yala F; Couroucé AM; Arthaud ML; Nerelli B; Biendo M; Wassoumbou E
    Bull Soc Pathol Exot; 1990; 83(2):155-8. PubMed ID: 2145083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative immunogenicity of 2 recombinant hepatitis B vaccines (GeneVac-B and Engerix-B) in adult patients with chronic renal failure.
    Rajapurkar MM; Gang S; Dabhi M; Kulkarni PS
    J Nephrol; 2007; 20(5):596-601. PubMed ID: 17918146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B vaccine: clinical trials in high-risk settings in France. (September 1975-September 1982).
    Goudeau A; Dubois F; Barin F; Dubois MC; Coursaget P
    Dev Biol Stand; 1983; 54():267-84. PubMed ID: 6228468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunogenicity and safety of recombinant yeast-derived hepatitis B vaccine (YDV) on adults].
    Shi J; Li Z; Zheng L
    Zhonghua Liu Xing Bing Xue Za Zhi; 2001 Apr; 22(2):105-7. PubMed ID: 11860855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low dose hepatitis B vaccination in children.
    Milne A; Allwood GK; Pearce NE; Lucas CR; Krugman S
    N Z Med J; 1986 Feb; 99(795):47-9. PubMed ID: 2935755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and immunogenicity of a recombinant hepatitis B vaccine in neonates.
    Gunn TR; Bosley A; Woodfield DG
    N Z Med J; 1989 Jan; 102(860):1-3. PubMed ID: 2521527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults.
    Van Damme P; Leroux-Roels G; Law B; Diaz-Mitoma F; Desombere I; Collard F; Tornieporth N; Van Herck K
    J Med Virol; 2001 Sep; 65(1):6-13. PubMed ID: 11505437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of a new, low-cost recombinant hepatitis B vaccine derived from Hansenula polymorpha in adults.
    Kulkarni PS; Raut SK; Patki PS; Phadke MA; Jadhav SS; Kapre SV; Dhorje SP; Godse SR
    Vaccine; 2006 Apr; 24(17):3457-60. PubMed ID: 16530299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.